Abstract
Patients with programmed death-ligand 1 positive (PD-L1+), locally advanced or metastatic, squamous non-small cell lung cancer (NSCLC) have a poor prognosis and more effective treatments with better tolerability profiles are needed. Sitravatinib, a selective tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor cells and regulatory T cells, which promotes expansion and migration of antitumor cytotoxic T cells, and increases the ratio of M1/M2-polarized macrophages. Tislelizumab, an anti-programmed cell death protein 1 (PD-1) antibody engineered to minimize binding to FcγR on macrophages, has shown clinical activity in patients with advanced solid tumors, including NSCLC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
